

1 *Review*

2 **Enteral Nutrition in Patients with Inflammatory** 3 **Bowel Disease: Systematic Review, Meta-Analysis** 4 **and Meta-Regression**

5 **Jose M. Chomeche-Gujarro¹, Pablo Caballero^{1*}, Ana Gutierrez-Hervas², Sofia García-Sanjuan²,**
6 **Iris Comino¹, Cesare Altavilla¹, Jose Tuells¹**

7 ¹ University of Alicante. Department of Community Nursing, Preventive Medicine and Public Health and
8 History of Science. (SPAIN)

9 ² University of Alicante. Department of Nursing. (SPAIN)

10 * Correspondence: pablo.caballero@ua.es

11

12 **Abstract:** Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system
13 and characterized by the inflammation of the gastrointestinal tract. One of the possible treatments
14 for this pathology is a change in the type of diet, the enteral nutrition (EN) is one of them. This study
15 is to understand how the use of EN can affect the adult population diagnosed with IBD. We
16 conducted a systematic review, meta-analysis and a meta-regression. On the different databases,
17 (MEDLINE, Scopus, Cochrane, LILACS, Cinhal, WOS) we found 363 registers, the accuracy was 12%
18 (44 registers); After a Full-text review, only 30 research studies were selected for qualitative
19 synthesis and 11 for Meta-analysis and Meta-regression. The variables used were Crohn's Disease
20 Activity Index (CDAI), C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR). EN has
21 shown to have efficacy for the treatment of Crohn's Disease and is compatible with other medicines.
22 As for the CDAI or the rates of remission, there were no differences between enteral and parenteral
23 nutrition. Polymeric formulas, have shown better results with respect to the CRP. The long-term
24 treatment could dilute the good CDAI results that are obtained at the start of the EN treatment.

25 **Keywords:** Inflammatory Bowel Diseases; Enteral Nutrition; Systematic Review; Meta-Analysis;
26 Crohn Disease.

27

28 **1. Introduction**

29 Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system and
30 characterized by the inflammation of the gastrointestinal tract. IBD includes Crohn's disease (CD) as
31 well as ulcerative colitis (UC) [1]. UC affects the large intestine and is generally observed as a
32 superficial ulcer due to an inflammatory reaction localized to the mucosa and the submucosa.
33 However, CD occurs all along the intestinal tract (from mouth to anus), and involves the entire
34 intestinal layer [2].

35 The prevalence and incidence of IBD has increased worldwide and is increasingly diagnosed in
36 young individuals [3]. As it is a chronic, incurable and low-mortality disease, it is expected that the
37 decrease of the global burden of the disease in the next decade will require a two-pronged solution
38 that implies research on prevention interventions, as well as innovations in the care of these patients
39 [3,4].

40 The etiology of the IBD is still greatly unknown, and recent evidence indicates that the genetic
41 susceptibility of the individual, the environment, the intestinal microbial flora, and the immune
42 responses are all factors involved and functionally integrated in the pathogenesis of the IBD [5]. IBD
43 can provoke various symptoms that include abdominal pain, low fever, fatigue, weight loss,
44 abdominal pain, diarrhea, bloody feces, etc. [6].

45 Within the identification of the environmental risk factors, diet is one of the most important, as
46 it regulates intestinal inflammation by modifying the intestinal microbiota, having an effect on the
47 gastrointestinal permeability [7,8]. Therefore, it can induce the expression of disease genes and
48 determine the cell's phenotype and function in IBD [7,8]. One of the possible treatments for this
49 pathology is a change in the type of diet [9].

50 One of the potential changes in diet is the use of enteral nutrition (EN), which is based on the
51 administration of enteral foods/formulas through different means. These foods are nutritionally-
52 complete liquid mixtures of pre-digested foods that have carbohydrates such as simple sugars, fats
53 such as different types of oils, nitrogen as protein, along with vitamins and minerals [10]. Within the
54 elemental formulas, different classes can be distinguished as a function of the nitrogen source:
55 elemental formulas are based on amino acids; semi-elemental formulas are based on oligo-peptides,
56 and polymeric formulas are based on whole proteins [11].

57 Diverse authors have highlighted that EN, especially in the form of exclusive enteral nutrition
58 (EEN), is a type of therapy established to induce the remission of CD in the infant population,
59 although its role as a first line therapy for CD in adults has not been defined yet and its mechanism
60 of action for palliating the symptoms of IBD is not completely understood [9,12]. Authors such as
61 Guagnozzi et al. suggest that the interaction between the composition of specific dietary formulas or
62 nutrients and IBD should be investigated to add new knowledge on the etiopathogenesis of the
63 disease in the nutritional intervention [13].

64 Therefore, the main objective of this study is to understand how the use of EN can affect the
65 adult population diagnosed with IBD.

66 2. Materials and Methods

67 To achieve this objective, a systematic review was conducted in agreement with the procedures
68 and verification list described by PRISMA [14]. Afterwards, a meta-analysis on the more common
69 results, and a meta-regression with the co-variables, type of enteral nutrition and period of treatment,
70 were conducted.

71

72 2.1. Systematic Review

73

74 A search of scientific works was conducted in the MEDLINE database, through the system of
75 open retrieval system on the Internet such as PubMed, Cochrane, Scopus, Web of Science, Cinhal and
76 LILACS. The studies conducted over time, up to Jan 5th, 2019, were compiled.

77

78 2.1.1. Inclusion and exclusion criteria

79 The studies selected had to comply with the following inclusion criteria: refer to an adult
80 population (older than 18) diagnosed with some type of IBD; study the effect of enteral nutrition
81 within IBD; be clinical trials; in English, Spanish, Portuguese, French or German languages.

82 The following articles were excluded: those that referred to the infant population; to animals, to the
83 use of EN in a healthy adult population; those that sought the effect of oral exclusion diets on IBD;
84 that were observational studies; that were based on secondary sources.

85

86 2.1.2. Search equation

87 To include content linked to the intervention, EN, a specific descriptor was used (MeSH), such
88 as "Enteral Nutrition", and the term "Enteral Nutrition" in the title or abstract.

89 For the content linked to the population, we utilized the descriptor that referred to the disease
90 "Inflammatory bowel diseases", and its equivalent term in the title or abstract.

91 Also, the filters "Humans", "Adult" and "Clinical Trial" were utilized to achieve our objective.

92 Therefore, the main search equation designed for this study was:

93 ("Inflammatory Bowel Diseases"[Mesh] OR "Inflammatory Bowel Diseases"[Title/Abstract])
94 AND ("Enteral Nutrition"[Mesh] OR "Enteral Nutrition"[Title/Abstract])) AND (Clinical Trial[ptyp]
95 AND Humans[Mesh] AND adult[MeSH])

96 The search equation was adapted to each and all of the databases described previously. The
97 process was conducted between the months of May and June, 2019.

98 2.1.3. Selection process

100 After eliminating the duplicate records, the process of selection was conducted in two phases.
101 The first consisted in reviewing the titles and abstracts of all the article records resulting from the
102 adapted search equations and shown by the databases, by using the inclusion and exclusion criteria
103 and the objective of the study as the screening measure. The screening and selection of the
104 records/articles was conducted independently by the two researchers, both experts in the fields of
105 nutrition. These researchers agreed on the discrepancies found in order to define the final suitability
106 of the records/articles found in the databases. The precision of the search was calculated, based on
107 the ratio of the full-text articles selected for the review divided by the number of records found by
108 the search equation, multiplied by one hundred.

109 The second phase was conducted by applying the inclusion/exclusion criteria to the complete text
110 of all the scientific studies selected in the first phase, thus ensuring the relevance of each one of them.

112 2.1.4. Evaluation of the quality of the studies

113 The evaluation of the methodological quality of the included studies was performed by two
114 independent researchers, using the Jadad scale for clinical trials. This scale is separated into three
115 sections, one for randomization, one for blinding, and another to inform about withdrawals and
116 drop-outs. The maximum attainable score is 5 points for each clinical trial. The research studies that
117 achieve a score 1 point or higher out 5 were considered to be of high-quality [15–18].

119 2.2. Meta-Analysis and Meta-Regression

120 To calculate the effect size of the enteral nutrition on the variables: Crohn's Disease Activity Index
121 (CDAI), C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), a meta-analysis was
122 performed. For this, the model of fixed effects and the model of random effects were utilized. The
123 results were presented as a forest-plot, along with the percent Heterogeneity and its confidence interval
124 at 95%, the T value and the heterogeneity test.

125 To explore the influence of each study over the effect size we used a leave-one-out method; pooled
126 estimates were calculated omitting one study at a time. In addition, we plotted a scatter plot introduced
127 by Baujat et al. [19] On the x-axis, the contribution of each study to the overall heterogeneity statistic is
128 plotted. On the y-axis, the standardized difference of the overall treatment effect with and without each
129 study is plotted; this quantity describes the influence of each study on the overall treatment effect.
130 Therefore, studies that fall on the top right quadrant of the Baujat plot have the most influence.

131 Publication bias occurs when only favorable results are published, and this could have
132 consequences on the results of the meta-analyses if these were included. To analyze the publication
133 bias, a non-parametric analysis was conducted as proposed by Duval and Tweedie [20] based on the
134 funnel-plot, estimating and adjusting for the number and outcomes of missing studies in the meta-
135 analysis. Another less-conservative proposal to estimate the number and outcomes of missing studies
136 is the proposal by Copas et al. [21].


137 The meta-regression was utilized to understand if the type of enteral nutrition (Polymeric or
138 Elemental), age (years) or the duration of the intervention (days), modified the effect size of the resulting
139 variables CDAI, CRP and ESR as a function of the type of nutrition. All the calculations were conducted
140 within an R programming environment utilizing the packages meta version 4.9-6 [22] and metasens
141 version 0.4-0 [23].

143 3. Results

144 3.1. Systematic Review

145 As a result of the specific search equations used on the different databases, a total of 438 records
 146 were found of scientific articles. A total of 75 records were duplicated, leaving a total of 363 records
 147 without duplication. In the first phase of the study, exactly 319 study records were discarded,
 148 leaving 44 full-text studies to review, so that the accuracy was 12%. The reasons for not including
 149 them were that 131 records showed that the study utilized a design that was not adequate, 100 did
 150 not use an adult population, 50 did not study the effect of EN, 3 were written in another language
 151 other than the ones cited above, (2 in Japanese and 1 in Chinese), 12 did not refer to humans, 6 did
 152 not refer to the IBD, and 17 were still being conducted, without showing results (Figure 1).

153 In the second phase, 7 studies were not utilized as they could be obtained in electronic format,
 154 not even after contacting the authors. In addition, 7 trials were removed, one for being written in
 155 Turkish, another due to defects in its design, another for not studying the effects of EN, and 4 because
 156 the population studied was not diagnosed with IBD. Therefore, only 30 research studies [10, 24-52]
 157 were selected, as shown in Figure 1.
 158




159
 160 **Figure 1.** Identification and selection of studies/records in the databases.
 161
 162

159
 160
 161
 162
 163
 164
 165

As for the designs of the studies included, 16 controlled and randomized clinical studies (53.3%), 9 non-randomized, controlled clinical trials (30%) and 5 non-randomized, non-controlled clinical trials (16.7%) were found. In addition, 28 of the studies found showed results that specifically

166 referred to CD and 2 studies had results on UC and CD, under the category of IBD. Also, 23 studies
 167 mentioned results of the disease in its active form, 4 studies in the shape of remission, and the rest
 168 did not indicate it. Figure 2 shows this information in a chronological manner.
 169



170 **Figure 2:** Chronological review according to type of study and population.
 171

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

As for the variety of the types of formulas employed, 19 studies utilized an elemental formula, 11 studies utilized a polymeric formula, 2 studies a semi-elemental formula, and 3 studies a type of parenteral nutrition (PN). Likewise, it should be mentioned that various types of formulas were often used in a same study. Thus, the following commercial formulas were employed: "E028", "Novasource", "Peptisorb", "Elental", "E028 Extra", "Vivonex-TEN", "Peptison", "Peptamen", "Vivonex HN", "Reamentyl", "Triorsbon", "Vital", "Vivonex", "Fortison", "Precision-Isotonic", "Uniasa", "Guarantee Plus" and "liquid Pepti-2000 LF".

In addition, a total of 6 types of objectives were found: Ten studies sought to compare two different types of EN, among which 5 of the works compared an elemental formula with a polymeric one, 2 compared an elemental formula with another elemental one that contained a greater concentration of fats, 1 work compared two types of polymeric formulas, 1 work compared two types of elemental formulas and 1 work compared an elemental formula with a semi-elemental one.

Moreover, 7 studies compared a type of EN with an oral diet, 5 studies sought to experiment with a type of EN, 3 studies compared a type of EN with a type of PN, 3 studies sought to compare a type of EN with another type of medication plus an oral diet, and lastly, 2 studies sought to compare a partial EN plus a diet, with an oral diet.

As for the manner of administration of the EN, 15 research studies employed a nasogastric tube, 3 studies utilized a nasoduodenal catheter, 2 studies used a nasointestinal catheter, 7 studies administered the formula orally, and 3 did not specify the manner of administration.

The total population analyzed in the research studies found included a total of 1070 individuals with IBD, with 1016 diagnosed with CD and 25 with UC.

193 The main tools utilized by the researchers to obtain results were: Scores, biomarkers and tests to
194 measure the activity of the disease: "Harvey-Bradshaw Index" (HBI), the CDAI, the Van Hees activity
195 index (VHAI), the qualification in the classification of the International Organization of Inflammatory
196 Bowel Disease (IOIBD), the Subjective Global Assessment (SGA), the Truelove and Witts index, the
197 simple clinical index, the Crohn's disease activity score (CDAS); biomarkers such as CRP, ESR, the
198 white blood cell count (WBC), levels of albumin, pre-albumin, transferrin, hemoglobin, platelet count,
199 total bilirubin, alkaline phosphatase, etc.; and medical tests such as the ileocolonoscopy. Specific
200 quality of life questionnaires such as the "Inflammatory Bowel Disease Questionnaire" (IBDQ).
201 Complementary tests such as urine and feces samples. Tests of measure the body's composition, such
202 as anthropometries and bioimpedence.

203 Table 1 shows the main results schematically, found in the selected articles and Table 2 shows
204 the scores obtained by the studies for their methodological quality according to the Jadad scale. A
205 mean score of 2.0 was obtained for all the studies, and a mean score of 2.1 for all the studies included
206 in the meta-analysis.

207
208
209

Table 1. Main Results of the Systematic Review

Author	Study	n/age	Disease	P/d	CC	Treatment	Variables	Main Results
Walton et al 2016[10]	UNRCT	17/?	ACT CD	14	GB	Enteral feeding E028 extra (Elementary diet)	CRP, HBI and automated spectral identification in feces	The HBI decreased from 6.88 ± 2.93 to 4 ± 5.50 , ($p < 0.05$), the CRP from 36.0 ± 41.3 mg / l to 8.11 ± 3.59 ($p < 0.05$, the concentration of 1-propanol and 1-butanol decreased too. No modifications in phenol and indole. The SCFA esters disappeared.
Pinar Sökülmez et al 2014[24]	RCCT	38/37 M 28 F 10	ACT IBD EG/CG: 15/23 CD EG/CG: 6/7 UC EG/CG: 9/16	21	TR	EG/CG Diet and EN Novasource® / Unrestricted Diet	SGA, BMI, nausea, vomiting, bowel movements, change in malnutrition state, general status, and disease severity.	Although at the beginning of the study the proportion of patients with a severe UC in the EG was higher than in the CG (8/9, and 7/16 respectively), there were no significant differences at the end of the study ($p > 0.05$). In both groups the improvements in disease activity of patients with UC were significant, but non-significant positive changes were observed in the clinical findings during the hospitalization period. Significant improvements of the SGA in both groups.
Dong Hu et al 2014[25]	UNRCT	59/32 M 42 F 17	ACT CD	84	CN	Elemental formula Peptide (Nutricia) through nasogastric or nasointestinal tube, plus water and weak tea.	Symptoms, CDAI, peripheral blood samples. Laboratory tests, including nutritional parameters and inflammatory parameters and CT.	50 patients achieved a partial remission, 30 a complete remission. 48 symptomatic remission, 35 radiological remission and 42 clinical remission. The CDAI decreased from 188.2 to 132.4 in 21 days ($P < 0.05$), and to 92.9 after 81 days ($P < 0.05$). Significant decrease in the thickness of the intestinal wall and an increase in the area of the luminal cross section. CRP and ESR decreased significantly ($P < 0.05$), the BMI, albumin, prealbumin and transferrin, HB, platelets, red blood cells, globulin and total protein increased significantly ($P < 0.05$).
Zhen Guo et al 2013[26]	UNRCT	13/26 M=9 F=4	ACT CD	28	CN	Exclusive EN through polymer formula Administration: Nasogastric tube at night and orally by day. They allowed water consumption.	IBDQ, CDAI, BMI, CRP, ESR, WBC count, HB and serum albumin level in peripheral venous blood.	11 patients achieved clinical remission and 2 did not. CDAI and CRP decreased from 232.2 and 34.6 to 84.7 and 4.0 ($P \leq .001$). Significantly decreased the number of liquid or soft stools, abdominal pain, general well-being and percentage deviation of the standard weight ($p < 0.05$), no differences were found in the presence of complications, taking atropine/diphenoxylate or opiates, presence of a mass abdominal and hematocrit. There were significant improvements in the IBDQ, from 128.3 to 182.9 ($p < 0.001$). Significant improvement in all categories: intestinal symptoms (from 41.5 to 62.0, ($p < 0.001$), systemic symptoms (16.5 to 27.5, $p < 0.001$), social function (20.5 to 26.5, $p = 0.03$) and emotional state (49.8 to 66.9, $p < 0.001$). Correlation between IBDQ and CDAI after treatment ($r = -0.57$; $p = 0.042$).

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Disease	P/d	CC	Treatment	Variables	Main Results
Feng Y et al 2013[27]	NRCCT	24/33 M 17 F 7	ACT CD ENG/NoEN/CG 8/8/8	28	CN	ENG: Enteral formula "Peptisorb" by nasogastric tube, plus water. NoENG: EC patients without EN. CG: Patients with colon carcinoma.	Adipocyte size, adipokine production and level of CRP were evaluated. Leptin, resistin, TNF, and IL-6 and IL-10 levels were determined. BMI, CDAI, etc. were calculated.	ENG patients had a higher BMI level and lower levels of CRP and CDAI (p<0.001) and achieved clinical remission (CDAI<150). In addition, protein levels of proinflammatory adipokines (TNF-alpha and leptin) were lower, leptin was negatively regulated, and adipokine expression (mRNA level) was positively regulated. In the NoEN group the level of adiponectin protein was higher
Dawn M. Wiese et al 2011[28]	NRCCT	20/46 M 4 F 16	ACT CD EPA>2%/EPA<2% 10/10	120	US	Two 8-oz each day of NE EPA>2% or EPA<2% respectively.	CDAI, IBDQ, nutritional status, micronutrient levels, CRP and body composition among others were measured.	EPA> 2% group increased the BMI, fat mass, fat-free mass, IBDQ (+41.4 [23.1, 47.0]; p=0.002) and the CDAI decreased (-47.8 [-65, -37.8]; P = 0.05). There were no differences between groups for the rest of the variables studied.
Takayuki Yamamoto et al 2010[29]	NRCCT	56/32 M 36 F 20	REM CD EG/CG 32/24	392	JP	EG.Elemental formula "Elental" by nasogastric tube at night and low-fat foods during the day. CG. Unrestricted Diet	WBC, HB, hematocrit, platelet count, ESR, CRP and albumin. CDAI. Symptoms, adverse effects, stool parameters.	The CDAI did not decrease significantly. No differences were observed between the groups. (P = 0.51). The cumulative proportion of patients in clinical remission was not significantly different between the groups.
Takayuki Yamamoto et al 2006[30]	NRCCT	40/32 M 26 F 14	ACT CD EG/CG 20/20	+365	JP	EG.Elemental formula "Elental" by nasogastric tube at night and low-fat foods during the day. CG. Unrestricted Diet	WBC, HB, platelet count, ESR, CRP and albumin. CDAI and parameters by ileocolonoscopy.	During the year of follow-up, 1 patient of the EG and 7 in the CG developed clinical recurrence (p = 0.048). At 6 months, 5 patients of the EG and 8 of the CG developed endoscopic recurrence (odds ratio, 2.0; p=0.50). At 12 months, 6 patients from the EG and 14 from the CG showed endoscopic recurrence (odds ratio, 5.4; p=0.027)

Table 1: Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Disease	P/d	CC	Treatment	Variables	Main Results
S. Takagi et al 2006[31]	RCCT	51/30 M 37 F 14	REM CD EG/CG 26/25	730	JP	EG: Half of calories, elementary diet through a enteral or oral intake and the remaining half by regular meals . CG: Unrestricted Diet	CDAI. Parameters of: feces, symptoms and laboratory tests.	After an average follow-up of 11.9 months, the relapse rate in the EG was significantly lower than in the CG [34.6% vs 64.0%; Multivariate risk ratio 0.40 (95% CI: 0.16-0.98)]. No significant changes on the rest of the variables
Tadao Bamba et al 2003[32]	RCCT	28/28 M 17 F 11	ACT CD Low / Medium/ High Fat EN 10/10/8	28	JP	LOWG: 6 packages of elemental diet "Elental" and 6 packages of dextrin MEDG: 6 packages of elemental diet "Elemental", 3 packages of dextrin and 3 packages of dextrin C-1 (dextrin + soybean oil). HIGHG: 6 packages of elemental diet "Elemental" and 6 packages of dextrin C-1. Administration: Nasogastric tube.	IOIBD, inflammatory markers (CRP, ESR) and body weight were recorded at each follow-up.	No differences in body weight gains. The LOWG's IOIBD was significantly higher than in the MEDG and HIGHG groups (p = 0.048) and the CRP lower after the first week. In the MEDG and HIGHG groups the CRP fluctuated during the study. In the LOWG group the ESR decreased, but for the other groups they remained high or increased during the study. Clinical remission was achieved in 8, 4 and 2 patients in the LOWG, MEDG and HIGHG groups respectively. This remission rate is significant if grouped in LOWG vs.. MEDG & HIGHG (p = 0.046).
M A Gassull et al 2002[33]	RCCT	62/29 M 24 F 29	ACT CD PEN1/ PEN2/ ESTG 20/23/19	28	ES GB DE	PEN 1: Polymeric EN, rich in n9 monounsaturated fatty acids (MUFA) (oleic acid). PEN 2: Polymeric EN rich in n6 polyunsaturated fatty acids (PUFA) (linoleic acid) ESTG (Steroid group): Prednisone.	ESR, CRP, serum fibrinogen, VHAI, CDAI, NRI, serum albumin and grip strength	The intention-to-treat analysis showed that the remission rates were 20%, 52% and 79% for PEN1, PEN2 and ESTG (p = 0.001). Withdrawal from treatment, remission rates were 27%, 63% and 79%, respectively (p = 0.008). No differences in remission time and changes in activity rates, inflammatory biological parameters, NRIs and nutritional variables.
Toshihiro Sakurai et al 2002[34]	RCCT	36/26 M 30 F 6	ACT CD=36 EDG/TLG 18/18	42	JP	EDG: "Elental" Formula (Ajinomoto Pharma) low in fat. TLG: Twinline Formula (Otsuka Pharma) large amount of medium chain triglycerides Administration: Tube in the duodenum.	CDAI, VHAI, CRP, ESR, levels of: serum albumin, plasma prealbumin, plasma transferrin and retinol binding protein in plasma and triene / tetraeno ratio.	After 2 weeks, serum levels of linoleic acid, an omega 6 fatty acid, decreased significantly in the EDG group. Without significant differences was observed: a short-term remission in 67% in the EDG and 72% in the TLG, a reduction in the CDAI and the VHAI, a normalization of the CRP and an improvement in the ESR and levels serum; albumin, plasma prealbumin, plasma transferrin and plasma retinol binding protein, the linolenic acid levels decreased in both groups.

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Disease	P/d	CC	Treatment	Variables	Main Results
S. Verma et al 2000[35]	NRCCT	39/40 M 12 F 27	REM CD EG/CG 21/28	365	GB	EG: Oral nutritional supplementation with elemental diet "EO28 Extra", plus normal diet. CG: Unrestricted Diet.	CDAI, inflammatory markers such as CRP, ESR, albumin, HB and platelet count.	The intention-to-treat analysis showed that the remission rates were 48% and 22% for EG AND CG (p=0.0003). Withdrawal from treatment, remission rates were 60%, and 22%, respectively (p <0.00001). Without showing significant differences were observed: a stability of the levels of CDAI and albumin and an increase in BMI. A significant decrease in ESR was observed. Clinical remission was achieved in 8 (80%) and 6 (55%) patients in the GA and GP groups, respectively (without significant differences, p=0.1). In both groups CDAI (GA, 359 ± 67 to 112 ± 19, p ≤ 0.0002; GP, 303 ± 27 to 97 ± 11, p ≤ 0.0005) and CRP (GA, 16 ± 5 to 4 ± 1.6, p<0.1; GP, 62 ± 20 to 9 ± 6, p<0.04) decreased. Remission was achieved earlier in GA (7 ± 2 days) than in GP (14 ± 2 days) (without significant differences). Overall, enteral feeding was successful in 14 patients (63%).
Verma S et al 2000[36]	RCCT	21/35 M 8 F 13	ACT CD GA/GP 11/10	28	UK	GA: Free amino acids diet. GP: Polymeric diet. Administration: nasogastric tube. Water was allowed.	CDAI, inflammatory markers (CRP, etc.), BMI and body weight.	The REE did not change. From day 7 the UNP, RQ and RQ without proteins increased significantly. These changes (except carbohydrate oxidation rates) were reversed when the EN was interrupted.
Bruno Schneeweiss et al 1999[37]	NRCCT	26/28 M 9 F 17	ACT CD EG/CG 7/19	15	AT	EG: 7 patients received enteral nutrition by nasogastric tube	Energy expenditure, UNP, changes in the body's urea nitrogen set and body composition.	Compared to the CG, the EG lost 11.3kg (p <0.0005), (5.1kg fat (p <0.0005), 2.2kg protein (p <0.025), 3.7kg water, 24.9g body potassium (p <0.01)). After EN, body weight (1.9 ± 0.3 kg; p <0.0005), body protein (0.3 ± 0.1 kg; p <0.025), fat (0.3 ± 0.1 kg; p <0.025) and water (1.1 ± more; 0.4 kg; p <0.025) was significantly increased. Body potassium increased but not significantly.
Dawna Royall et al 1995[38]	NRCCT	60/30 M 32 F 28	ACT CD EG/CG 30/30	21	CA	EG: one of two elementary diets, Peptamen or Vivonex-TEN, administered by nasoduodenal tube.	Total body protein, fat, water and body potassium.	16 patients (36.4%) achieved clinical remission and decreased CRP (p=0.05). Both groups had identical rates of remission, failure, early withdrawal and nasogastric feeding intolerance. There was an increase in serum albumin in patients who started the study at a low level.
Mansfield JC et al 1995[39]	RCCT	44/? M 16 F 28	ACT CD GA/GP 22/22	28	GB	GA: Enteral formula based on amino acids "Elemental 028". GP: Enteral formula based on oligopeptide-based diet "Pepti-2000 LF liquid". Water was allowed.	CDAI, laboratory activity measures (HB, platelet count, ESR, serum albumin concentration, AAGP and CRP) and body weight.	

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Pop.	P/d	CC	Treatment	Variables	Main Results
Teahon K et al 1995[40]	UNRCT	19/37 M 10 F 9	ACT CD	35	GB	Elemental diet "Vivonex" was using in one group (n=8) and "Elemental 028" in the other (n=11), by oral route.	CDAS, biochemical parameters (HB, platelet count, leukocytes, ESR, iron, magnesium, copper, zinc...), fecal parameters, BMI and body composition.	Changes were similar in both groups. Clinical disease activity and faecal excretion of leukocytes were significantly reduced after 2 weeks of treatment. Transferrin, prealbumin, albumin and serum iron were significantly increased at 4 weeks. Serum copper decreased during the study period. Changes in nutrition measures did not correlate significantly with changes in disease activity.
M.F.J. Stolk et al 1994[41]	UNRCT	6/27 M 3 F 3	CD	42	NL	By using a pump, the formula "Peptison" (Nutricia) was supplied.	Volume, motility, emptying and filling variables of the gallbladder were calculated, and concentration of CCK in the plasma	At the start of treatment, the fasting gallbladder volume decreased from 19.3 +/- 4.5 to 4.9 +/- 3.6 ml.. The CCK increased from 1.5 +/- 0.3 to 3.9 +/- 1.1 pmol / l.. After 8 days, the gallbladder contracted almost completely, the CCK increased to 7.5 +/- 2.7, and at 36 days, CCK increased to 8.3 +/- 2.6 pmol / l. After 22 days 22 the volume of the gallbladder increased, and after 46 the CCK decreased. This change was significantly greater than the CCK change on day 1 (p <0.05)
D Royall et al 1994[42]	RCCT	40/31 M 23 F 17	ACT CD AG/PG 19/21	21	CA	AG: Enteral formula based on amino acids "Vivonex-TEN". PG: Enteral formula based on peptides "Peptamen". Administered by nasogastric tube. Water was allowed.	CDAI, CRP, AAGP, phospholipids, albumin and transferrin. Body weight and total body nitrogen was evaluated.	After 21 days, remission rates were equivalent between the two groups: 84% for the AG and 75% for the PG (p = 0.38). At 12 months, it remained at 31% and 40% respectively (p = 0.39). Also, the reductions of CDAI, AAGP and CRP were significant. Linoleic acid decreased and total body nitrogen increased significantly in AG but not in PG (P <0.025). The concentration of phospholipids in plasma increased significantly in the PG
F González-Huix et al 1993[43]	RCCT	32/31 M 17 F 15	ACT CD PENG/ ESTG 15/17	28	ES	PENG: The polymeric EN administered by nasogastric tube. ESTG: Prednisone administration. And diet lactose-free while they were in the hospital.	VHAI, CRP. Evaluation of body weight, % IBW, MAMC, TSF, serum albumin concentration. Complete hematological and biochemical analysis.	There were no significant differences in the mean time (p = 0.47) and the number of patients who obtained clinical remission (p = 0.43). The VHAI decreased in both groups; PENG from 172.5 to 113.8, (p = 0.0001), ESTG from 184.3 to 118.1, (p = 0.0003). In both groups the CRP decreased and the serum albumin concentration increased significantly. After one year, 10 patients (66.6%) in the ESTG and 5 (41.6%) in the PENG relapsed. No differences in the cumulative probability of relapse.

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Pop.	P/d	CC	Treatment	Variables	Main Results
Hiroyuki Hirakawa et al 1993[44]	NRCT	61/25 M 39 F 22	REM CD ENG/ ENG+D/ DG/CG 25/22/8/6	60	JP	ENG: Elemental EN ("Elental") through nasoenteral tube. ENG+D: ½ ENG + ½ Low-fat diet and prednisolone DG: Low-fat diet and prednisolone CG: Unrestricted Diet	IOIBD, ESR and CRP	The cumulative rates of continuous remission after 1, 2 and 4 years were in the ENG 94%, 63% and 63%; in the ENG + D 75%, 66% and 66%, in the DG 63%; 42% and 0%, and in the CG 50%, 33% and 0%. The ENG had a higher rate than DG (P <0.05) and CG (P <0.01). The ENG + D had a higher rate than the CG (P <0.05). Patients who received more than 30 kcal of EN showed a higher continuous remission rate (P <0.001).
D Rigaud et al 1991[45]	RCCT	30/35 M 18 F 12	ACT CD EENG/ PENG 15/15	28	FR	EENG: Elementary enteral formula "Vivonex HN" PENG: "Realmentyl" polymeric formula	CDAI, fecal production, colonoscopies. Body weight; TSF, MAMC, daily urinary, creatinine-height ratio; blood levels of HB, albumin and transferrin. ESR, α2 globulin level and WBC counts.	The clinical remission was in the EENG of 66% and in the PENG of 73%. The CDAI and ESR levels were significantly reduced in both groups. There were no differences between groups for inflammatory markers, colonoscopic lesions, fecal production, body weight and creatinine index.
Herbert Lochs et al 1991[46]	RCCT	107/29 M 37 F 70	ACT CD OENG/CSG 55/52	42	DE	OENG: Enteral nutrition by oligopetidic formula "Peptisorb" through nasogastric or nasoduodenal tube. More tea or water. CSG: Combination of corticosteroids and sulfasalazine.	CDAI and laboratory tests.	After 6 weeks, 29 patients achieved remission in the OENG and 41 patients in the CSG (p <0.01). The remission time was significantly different (p <0.01). A CDAI below 150 was achieved in the OENG in 24 patients and in the CSG in 35. The CDAI and severe malnutrition parameters showed no significant differences in patients in remission.
A.H. Raouf et al 1991[47]	RCCT	24/?	ACT CD EENG/ PENG 13/11	21	GB	EENG: Enteral amino acid-based food "EO28" PENG: Whole protein-based whole food "Triosrbon". Administration: Oral, flavoured with Nesquick.	ESR, erythrocytes, VHAI, Bristol simple activity index and the CRP.	After 3 weeks, they reached remission in the EENG 9 patients and in the PENG 8 patients (p <0.01). The Bristol simple activity index improved in the two groups (EENG; 91.7%, PENG; 86.7% (p = 0.35)), Similarly; VHAI (EENG; 18.5%, PENG; 30.0%, (p = 0.23)), and CRP (EENG; 58.3%, PENG; 57.1%) (p = 0.49)).

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Pop.	P/d	CC	Treatment	Variables	Main Results
--------	-------	-------	------	-----	----	-----------	-----------	--------------

Richard A. Wright et al 1990[48]	RCCT	11/? M 7 F 4	ACT CD EENG/ PNG 6/5	14	US	EENG: Elemental enteral feeding "Vital" PNG: Determined peripheral parenteral nutrition.	CDAI, standard anthropometric parameters, nitrogen balance studies and chemical profiles.	CDAI improved significantly in both groups. Plasma transferrin levels and total lymphocyte count improved in the EENG group (p <0.05). No significant differences in weight gain.
Giaffer MH et al 1990[49]	RCCT	30/38 M 8 F 22	ACT CD AG/PG 16/14	28	UK	AG: Amino acids diet "Vivonex". PG: Polymeric diet "Fortison". Administration: nasogastric tube. Water was allowed.	CDAI, total body weight, MAMC, TSF and biochemical measurements such as serum albumin.	12 (75%) AG patients achieved remission at 10 days, compared with 5 (35.8%) in the PG group (p=0.03). CDAI decreased significantly in the AG group, not the PG group. The mean weight gain in both groups was similar. Mean serum albumin increased from 26g/l to 33g/l (p<0.001). Also, there were significant changes in ESR and AAGP in both groups.
Abad-Lacruz A et al 1990[50]	RCCT	22/32 M 15 F 14	ACT IBD PG/TPNG 16/13	NI	ES	PG: Polymeric diet high in nitrogen "UNIASA" by nasogastric tube. TPNG: Specific total parenteral nutrition by a central vein.	Biochemical measurements (total serum bilirubin, alkaline phosphatase, GGT, ALT, and AST) and VHAI and the Truelove and Witts index were measured.	PG had a significant increase in serum albumin concentration (32 ± 1 to 38.2 ± 1.6 g/litre; p <0.01). There was lower disease activity in both groups (3.31 ± 0.15 to 2.31 ± 0.24, p <0.05 in GP; and 3.38 ± 0.21 to 2.61 ± 0.27, p <0.05 in TPNG). 8 (5 CD and 3 UC) of 13 patients (61.5%) in the TPNG group developed abnormalities in LFT, while in the PG group only occurred in 1 of 16 patients (6.2%) (p = 0.002).
Greenberg GR et al 1988[51]	RCCT	51/30 M 25 F 26	ACT CD TPNG/ ENG/PPNG 17/19/15	21	CA	TPNG: Total parenteral nutrition, more water, plus daily one ampoule of vitamins. ENG: formula diet "Precision-Isotonic". PPNG: Unrestricted diet and a partial protein/calorie parenteral nutrition.	CDAI, nutritional assessment and biochemical measurements (hematocrit, blood glucose, serum electrolytes, creatinine, magnesium and albumin).	The average CDAI decreased (p <0.01) with no significant differences between groups. Remission rates to discharge were equivalent among the three groups: 12 patients in TPNG, 11 patients in ENG and 9 patients in PPNG and oral diet (X2 1.42 and 1.15; p = n/s). Remission rates of 42% in TPNG, 55% in EN and 56% in PPNG at 12 months were equivalent and not influenced by the type of nutritional support initially administered. At 12 months, 18 patients (35%) required surgery, 17 (34%) were medically treated for relapse, and 16 (31%) had sustained remission.

221

222

Table 1. Main Results of the Systematic Review (Cont.)

Author	Study	n/age	Pop.	P/d	CC	Treatment	Variables	Main Results
--------	-------	-------	------	-----	----	-----------	-----------	--------------

Harries AD et al 1983[52]	RCCT	28/37 M 17 F 11	ACT CD G1/G2 14/14	120	GB	G1: 2 months ordinary diet followed by 2 months supplementation with the non-elementary low-waste formula "Guarantee Plus". G2: same intervention than G1 with invested order.	Nutritional measurements (height, weight, MAMC and thickness of the skin fold), biochemical measurements (serum prealbumin, serum, red cell folate, creatinine height index, platelets, T lymphocytes, etc.) and urine tests parameters.	The general effect of EN during the 2 months was to increase serum albumin, serum protein and prealbumin levels, creatinine height index and T-lymphocyte count. With EN decreased levels of orosomucoids and serum alkaline phosphatase and its activity (p <0.05) Patients felt better when they received EN, although their monthly symptom scores showed no significant benefit.
---------------------------------	------	-----------------------	-----------------------------	-----	----	---	--	---

P/d; Period (days), CC: ISO Country Codes, UNRCT; Uncontrolled and non-randomized clinical trial, NRCCT; Non-randomized controlled clinical trials RCCT; Randomized controlled clinical trials UCT: Uncontrolled clinical trial, IBD= Inflammatory Bowel Disease, EG/CG; Experimental and Control Group, IBD; Inflammatory Bowel Disease, UC; ulcerative colitis, EN; Enteral Nutrition, CD: Crohn Disease, ACT: Active disease, REM: Disease in remission, M: Male, F: Female, CDAI: Crohn's Disease Activity Index; VHAI: Van Hees Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate, BMI: Body mass index, HBI: Harvey-Bradshaw Index, SCFA: Short chain fatty acid, SGA: Subjective global assessment, WBC: White blood cells, CT: computed tomography exam, HB: Hemoglobin, IBDQ: Inflammatory Bowel Disease Questionnaire, IOIBD: International Organization of Inflammatory Bowel Disease rating, NRI: Nutritional risk index, UNP: Urea Nitrogen appearance rate, RQ: Respiratory quotients, REE: resting energy expenditure, CCK: Cholecystokinin, AAGP: Alpha-1 acid glycoprotein, %IBW: Percentage of ideal body weight, MAMC: Mid-arm muscle circumference, TSF: Triceps skinfold thickness, HEEH: Home elemental enteral hyperalimentation, GGT: γ -glutamyltransferase, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LFT: Liver function test, TNF: Tumor necrosis factor, IL: Interleukin, htMAT: hypertrophied mesenteric adipose tissue, PTH: Parathyroid hormone, IBDNF: Inflammatory bowel disease nutrition formula, EPA: eicosapentaenoic acid, CDAS: Crohn's Disease activity score

223

224

Table 2. Quality assessment of clinical trials included in this review.

Studies	Mention to randomization	An appropriate method of randomization	Mention to blinding	An appropriate method of blinding	Reporting of withdrawals and dropouts	Total score
Walton et al 2016 [10]					*	1
Sökülmez et al 2014 [24]	*		*			2
D. Hu et al 2014 [25]			*		*	2
Z. Guo et al 2013 [26]					*	1
Y. Feng et al 2013 [27]					*	1
D. M. Wiese et al 2011 [28]					*	1
T. Yamamoto et al 2010 [29]					*	1
T. Yamamoto et al 2006 [30]			*			1
S. Takagi et al 2006 [31]	*	*				2
T. Bamba et al 2003 [32]	*	*			*	3
M. A. Gassull et al 2002 [33]	*	*	*	*	*	5
T. Sakurai et al 2002 [34]	*	*			*	3
S. Verma et al 2000 [35]					*	1
S. Verma et al 2000 [36]	*	*	*		*	4
B. Schneeweiss et al 1999 [37]						0
D. Royall et al 1995 [38]						0
J.C. Mansfield et al 1995 [39]	*	*			*	3
Teahon K et al 1995 [40]					*	1
M.F.J. Stolk et al 1994 [41]						0
D. Royall et al 1994 [42]	*	*	*	*	*	5
F. González-Huix et al 1993 [43]	*	*			*	3
H. Hirakawa et al 1993 [44]					*	1
D. Rigaud et al 1991 [45]	*	*			*	3
H. Lochs et al 1991 [46]	*				*	2
A.H. Raouf et al 1991 [47]	*				*	2
R. A. Wright et al 1990 [48]	*	*				2
M.H. Giaffer et al 1990 [49]	*				*	2
A. Abad-Lacruz et al 1990 [50]	*	*			*	3
G.R. Greenberg et al 1988 [51]	*	*	*		*	4
A.D. Harries et al 1983 [52]	*				*	2

According to the Jadad scale for reporting clinical trials [15,18]

226

227

228

3.2. Meta-Analysis and Meta-Regression

229

Only 11 clinical trials had common quality and variables needed to be used in the meta-analysis.

230

These 11 trials worked with a total of 15 groups. The final size of the sample was comprised by 272

231

individuals, all with CD, to which an EN treatment had been given. The common variables were the

232

CDAI, the CRP and the ESR, and the co-variables type of nutrition, age and duration of the

233

intervention. Figure 3 shows the effect size of the use of EN. For the three indicators of disease, the

234

effects are positive when comparing the situation at the start and finish of the treatment with EN,

235

independently if the situation with fixed effects (less probable) or random effects (more acceptable)

236

is considered.


237

238


239

240


241



(a)



(b)



(c)

Figure 3. Forest plot for: (a) Crohn's Disease Activity Index (CDAI), (b) C-Reactive Protein (CRP), (c) Erythrocyte Sedimentation Rate (ESR).

242

243

244

245

The influence of each study on the results of the meta-analysis are shown on table 3, considering a model of random effects. Figure 4 shows this influence through the Baujat plot. The numbers shown in the figure correspond to the articles shown on the table in the ID column.

246

247

248

249

250

251

Table 3. Influence analysis in meta-analysis using leave-one-out method (Random effect)

meta-analysis for:						
Effect size (%Heterogeneity)						
ID	Omitting	KN	n	CDAI	CRP	ESR
1	M.H. Giaffer et al 1990	Pol	14			13.0 (96.8%)
2	M.H. Giaffer et al 1990	Elm	16			13.1 (93.7%)
3	D. Rigaud et al 1991	Pol	15			11.2 (97.6%)
4	D. Rigaud et al 1991	Elm	15			10.4 (97.6%)
5	F. Glez.-Huix et al 1993	Pol	15		20.0 (97.4%)	11.1 (97.6%)
6	D. Royall et al 1994	Elm	19		22.2 (95.1%)	
7	D. Royall et al 1994	Pol	21		22.3 (97.4%)	
8	Teahon K et al 1995	Elm	19			11.0 (97.6%)
9	S. Verma et al 2000	Pol	10	136.9 (94.0%)	17.5 (97.3%)	11.5 (97.6%)
10	S. Verma et al 2000	Elm	11	128.0 (97.2%)	21.9 (97.6%)	10.9 (97.6%)
11	D. M. Wiese et al 2011	Pol	20	162.3 (97.8%)		
12	Yun Feng et al 2013	Pol	8	150.3 (97.9%)	19.7 (96.6%)	
13	Zhen Guo et al 2013	Pol	13	146.7 (97.8%)	19.6 (97.5%)	10.4 (97.6%)
14	Dong Hu et al 2014	Elm	59	162.7 (92.6%)	21.5 (97.4%)	9.8 (91.2%)
15	C. Walton et al 2016	Elm	17		20.1 (97.6%)	
Pooled estimate				145.7 (97.4%)	20.5 (97.2%)	11.3 (97.4%)

KN: Kind of nutrition; Pol: Polymeric Nutrition, Elm: Elemental Nutrition, CDAI: Crohn's Disease Activity Index; VHAI: Van Hees Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.

252
253
254
255




Figure 4: Baujat plot for: (a) Crohn's Disease Activity Index (CDAI), (b) C-Reactive Protein (CRP) and (c) Erythrocyte Sedimentation Rate (ESR). The correspondence between the study and the number is shown on table 2 (Id, Omitting)

256
257
258
259
260
261

The results show that the articles do not influence the results in the case of the CDAI and the ESR, however, study 6 (D. Royall et al 1994 with Elemental Nutrition) and to a lesser degree, study 12 (Yun Feng et al 2013 with Polymeric Nutrition) could be the ones that may compromise the results of the meta-analysis for the CRP. However, the heterogeneity, omitting these works, was 95.1% and 96.6%,

262 as compared to the overall 97.2%, therefore, a great influence of the CRP on the meta-analysis cannot
 263 be determined.

264

265 A Funnel Plot represents the effects observed in the different studies (x-axis), and the standard error
 266 (y-axis). In the absence of heterogeneity and publication bias, the dots shown in the funnel plot
 267 should jointly adopt the aspect of a funnel, with the wider part corresponding to the smaller and
 268 more precise studies. A lack of symmetry could be due to this publication bias. The funnel plot is
 269 shown in Figure 5, and a lack of symmetry can be observed. Therefore, the non-parametric analysis
 270 proposed by Duval and Tweedie to analyze this asymmetry should show a lack of articles, and
 271 therefore a publication bias. The results of this non-parametric analysis for the fixed-effects model
 272 and the random-effects model are shown on Table 4. These results show a possible publication bias
 273 in the three variables studied if a fixed-effects model is assumed; however, the random-effects models
 274 do not show this bias.

275

276




Figure 5. Funnel plot for: (a) Crohn's Disease Activity Index (CDAI), (b) C-Reactive Protein (CRP) and (c) Erythrocyte Sedimentation Rate (ESR).

277

278

279

280

281

282

Table 4. Number of studies that should be added and the estimated effect size.

	Trim-and-fill method				Copas Method	
	Fix model		Random model		Random model	
	Nº Studies	Effect size estimated 95%CI	Nº Studies	Effect size estimated 95%CI	Nº Studies	Effect size estimated 95%CI
CDAI	2	98.9 [43.9;153.8]	0	No Changes	0	No Changes
CRP	3	15.3 [9.7;20.9]	0	No Changes	4	18.0 [12.1;23.9]
ESR	5	19.3 [11.2;27.4]	0	No Changes	0	No Changes

Crohn's Disease Activity Index (CDAI), C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)

283

284

285 With respect to the meta-regression, the results are shown on Table 5. There is dependence of the
 286 CDAI score with the period, losing efficacy in prolonged interventions ($p < 0.05$). The CRP showed
 287 better results in the EN when using polymeric formulas that were elemental ($p < 0.001$).

288

289

290

291

292

Table 5. Meta-regression

Result	Co-variable		Test of Moderators	
	Intercep	KN*	QM	P-Value
CDAI	167.9	-33.8	0.289	0.591
CRP	13.7	12.6	3.977	<0.001
ESR	12.9	-3.0	0.106	0.745
	Intercep	Age	QM	P-Value
CDAI	225.5	-2.38	0.203	0.652
CRP	52.9	-1.0	0.985	0.321
ESR	48.3	-1.1	1.555	0.212
	Intercep	Period	QM	P-Value
CDAI	235.5	-1.9	5.662	0.017
CRP	21.4	-0.0	0.006	0.941
ESR	2.5	0.2	1.551	0.213

KN: Kind of nutrition, * Basis Elemental enteral nutrition.
Crohn's Disease Activity Index (CDAI), C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)

293

294 4. Discussion

295 Our results included 30 studies (1070 participants). All the trials included had a broad scope and
296 had a very varied methodological and clinical heterogeneity. The variables collected were very
297 diverse, with CDAI, CRP and ESR being the most common. The samples sizes of the studies included
298 were generally small ($n < 30$), thus, a meta-analysis was needed in order to arrive to better conclusions.

299 A cure for IBD is not known, however, there is evidence of remission and improvement of the
300 symptoms with EEN, which implies the exclusive consumption of an elemental or polymeric
301 substance for many weeks [53], as shown by many of our results. Despite the lack of correlation
302 between IBDQ and the CDAI, correlations were observed between both indexes starting at week 4 of
303 the treatment. A study which focused on the gall bladder was even found which showed its
304 improvement after day 36 of treatment administration; therefore, aside from reducing the activity or
305 inducing the remission of the disease, this diet could have beneficial effects on organs related with
306 the digestive system [26,28]).

307 The EN formulas tend to contain macronutrients such as amino acids or simple carbohydrates,
308 along with micronutrients such as vitamins. The proteins, carbohydrates and fats do not reach the
309 ileum or the colon as they are absorbed in the duodenum and jejunum. As for the amino acids they
310 contain, they are named elemental formulas if they contain free amino acids, semi-elemental if they
311 contain peptides, and polymeric if they contain whole proteins [54]. Different formulations exist,
312 but the ones that do seem to have a positive effect on the maintenance and remission of the disease
313 are elemental and polymeric diets [10,25]. The efficacy of an EN diet does not depend much on it
314 being elemental or polymeric, as shown by some of our results [45,47], since, a priori, both have the
315 same potential for inducing a remission [35,42,49]. However, the meta-regression conducted
316 indicated that a polymeric diet could decrease the CRP better than an elemental one. Also, a
317 distinction could be made between them when looking at the economic burden entailed by the use
318 of one or the other and the acceptability by the patients, meaning that, in the adherence to the dietary
319 treatment, the polymeric ones tend to be more accepted by the patients, as they are better
320 tasting[55,56]. The elemental foods are less tolerated with mouth feeding, and generally require a
321 nasogastric tube, which entails complication and the patient's discomfort. On the contrary, the

322 polymeric EN is more tolerable through the mouth by the patients, making it the first option for the
323 ill [36,57].

324 As for the formulation of the EN, studies have also been conducted on the benefits or not of an
325 EN diet rich in fats as opposed to an elemental EN. Just as in other studies, the results of the clinical
326 trials are controversial. Some studies have demonstrated the beneficial effect of the enteral formula
327 rich in fats [58], while others did not show any effect [59] or less beneficial effects [32]. Despite what
328 has been said, some studies suggest that an EN high in fats could improve the gastrointestinal
329 motility and improve the ileum after an operation [60], reducing damage to the intestinal mucosa
330 barrier and the underlying mechanism that could be associated with its antioxidant action after the
331 surgical intervention [61].

332 EEN combined with some type of medication such as antibiotics [62], seem to improve the
333 disease's symptoms, just as shown by our results, EN combined with other types of pharmaceuticals
334 such as prednisone, corticosteroids and sulfasalazines do show a significantly continuous high rate
335 of remission [44,63]. But on the other hand, the combination of EN with steroids does not seem to
336 have significant differences in the probability of a relapse [43], perhaps because the steroids do not
337 address the damage produced in the intestinal mucosa, which is the greatest predictor of
338 complications over time [64,65].

339 Although the mechanism that nurtures the healing of the mucosa by the ENN has not been
340 completely determined as of yet, it has been shown that a polymeric formula was as effective as the
341 Infliximab inhibitor of Tumor Necrosis Factor (TNF)- α , and higher than the hydrocortisone in the
342 maintenance of the function of the intestinal barrier [66]. This is perhaps the reason why significant
343 differences were not found in a study conducted by Gasull et al. in 2001 utilizing two polymeric EN
344 formulas, with the response being similar in both [33]. Also, in another study conducted with two
345 polymeric formulas for 5 weeks, a significant relationship was not found between the treatment with
346 different EN and the changes produced at the level of the disease's activity [40].

347 As for the use of elemental and semi-elemental EN, the results were very similar. For example,
348 Mansuf et al. achieved the clinical remission of 16 patients in 4 weeks with both formulas, and the
349 reduction of the CRP was significant in both groups [39]. The mechanism of action of the semi-
350 elemental diet could be multifunctional just as the elemental one, decreasing the intestinal
351 permeability and thus decreasing the loss of fluid. The semi-elemental diet could also reduce the
352 commensal intestinal bacteria that play a role in intestinal inflammation [67,68]. Thus, the use of these
353 types of diets is advisable, either with the use of an elemental or semi-elemental formula for the
354 management of different gastro-intestinal disorders [69].

355 In 2013, Yun Feng et al [27] found significant differences between groups subjected to EEN and
356 EN plus an oral diet, although it is interesting to note how the patients refer to a greater subjective
357 well-being when they take EN together with the oral diet, as compared to those who are not treated
358 with supplemented EN, despite the biochemical parameters being very similar [52,70]. Some studies
359 suggest that a partial enteral nutrition supplemented with different diets such as elimination, anti-
360 inflammatory, auto-immune diets, or diets low in FODMAP (Fermentable Oligo-, Di-, Mono-
361 saccharides And Polyols) could be beneficial for UC and CD [28,35], although larger controlled assays
362 are needed to back their use [71]. Even patients who were subjected to EN before their operation
363 experienced benefits, not only in their nutritional state, but also with a reduction of inflammation in
364 their disease [72], with patients also experiencing improvements after said intervention [30].

365 Historically, EN was used and is used as a complementary nutritional treatment for patients
366 with complicated IBD that lead to worrying malnutrition, improving their nutritional state [56].
367 However, the meta-regression from our study shows an inverse relationship between the period of
368 treatment with EN and the improvement shown through the CDAI, in that foreseeably, the patients
369 who are subjected to prolonged EN could stop noticing its benefits.

370 The EN was utilized as an induction therapy for the active IBD [56], but it is important to know
371 which EN formulas could be used to boost their anti-inflammatory effects, as there is evidence that
372 supplementary EN is not sufficient for inducing remission, so that it would have to be used
373 exclusively to be able to obtain its anti-inflammatory effect [73,74]. At present, it is well-established

374 that EEN has a strong anti-inflammatory effect with reduction of the systemic and mucosa
375 inflammatory parameters in a few days, however, the EEN as a long-term therapy is still a challenge,
376 give its lack of palatability and the lack of data that analyze the efficiency of EEN as a maintenance
377 diet [75].

378 Diverse studies have shown that clinical remission and healing of the mucosa is possible through
379 different nutritional regimes [76]. As for the debate about which is healthier, EN or PN, our results
380 show that there are studies in which the effectiveness of both seems to be significantly the same for
381 the improvement of the CDAI [48,51]. Having in mind that the dietary antigens could be important
382 stimulants for the immune system of the mucosa, the intestinal rest with total parenteral nutrition
383 (TPN), is considered as the main option for achieving this rest and for correcting possible nutritional
384 deficits [77]; however as compared to the EN, it seems not to provide greater benefits. In fact, in one
385 of the studies included in our review [50], it is the EN the one that seems to provide the greatest
386 benefits to the patients and to reduce the costs, personal as well as economic, of the different dietary
387 treatments [78].

388 According to European guidelines, the acceptability and the obligatory compliance of the EN
389 are the greatest obstacles found by the different researchers when dealing with the ENN studies.
390 There are clear differences between the studies shown in terms of healing of the mucosa, and
391 therefore the remission of the activity of the disease, which makes them difficult to compare. What is
392 known, however is that the EEN is a real alternative to immunosuppressive therapy, which exerts its
393 main therapeutic effect on the microbiota, promoting a reduction of the inflammation [79].

394 This study is not exempt of limitations. With respect to the systematic review, 7 articles were not
395 recovered, so that our results could be altered. However, the small variability observed through the
396 meta-analysis implies that these articles could substantially vary the results obtained, and in fact, the
397 sensitivity study that analyzed the publication bias showed little alterations on the effect size, as well
398 as its confidence interval. Although the quality of these studies has not been introduced in the meta-
399 regression, all the articles that were utilized with this technique were considered to have sufficient
400 quality, so that we do not believe that the quality could introduce bias in the findings.

401 5. Conclusions

402 EN has shown to have efficacy for the treatment of CD and is compatible with other medicines.
403 As for the CDAI or the rates of remission, there were no differences between EN and PN. The
404 polymeric formulas, as compared to the elemental ones, have shown better results with respect to the
405 CRP. The long-term treatment could dilute the good CDAI results that are obtained at the start of the
406 EN treatment.

407 **Author Contributions:** conceptualization, J.C., A.GH, S. GS and C.A.; methodology, J.C., C. A. and P.C. formal
408 analysis, J.C., I.C. and P.C.; investigation, J.C., A.GH, S. GS and I.C.; writing—original draft preparation, J.C. and
409 P.C.; writing—review and editing, A.GH, S. GS, I.C., J.T.; visualization, J.T.; supervision, J.T. and P.C.

410 **Conflicts of Interest:** The authors declare no conflict of interest

411 References

- 412 1. Celiberto, L.S.; Graef, F.A.; Healey, G.R.; Bosman, E.S.; Jacobson, K.; Sly, L.M.; Vallance, B.A.
413 Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation
414 of diet and the gut microbiome. *Immunology* **2018**, *155*, 36–52.
- 415 2. Cohen, L.J.; Cho, J.H.; Gevers, D.; Chu, H. Genetic Factors and the Intestinal Microbiome Guide
416 Development of Microbe-Based Therapies for Inflammatory Bowel Diseases. *Gastroenterology* **2019**, *156*,
417 2174–2189.
- 418 3. Coward, S.; Clement, F.; Benchimol, E.I.; Bernstein, C.N.; Avina-Zubieta, J.A.; Bitton, A.; Carroll, M.W.;
419 Hazlewood, G.; Jacobson, K.; Jelinski, S.; et al. Past and Future Burden of Inflammatory Bowel Diseases
420 Based on Modeling of Population-Based Data. *Gastroenterology* **2019**, *156*, 1345–1353.e4.

- 421 4. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.;
422 Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in
423 the 21st century: a systematic review of population-based studies. *Lancet* **2017**, *390*, 2769–2778.
- 424 5. Reddavid, R.; Rotolo, O.; Caruso, M.G.; Stasi, E.; Notarnicola, M.; Miraglia, C.; Nouvenne, A.; Meschi,
425 T.; De' Angelis, G.L.; Di Mario, F.; et al. The role of diet in the prevention and treatment of inflammatory
426 bowel diseases. *Acta Biomed.* **2018**, *89*, 60–75.
- 427 6. Eom, T.; Kim, Y.S.; Choi, C.H.; Sadowsky, M.J.; Unno, T. Current understanding of microbiota- and
428 dietary-therapies for treating inflammatory bowel disease. *J. Microbiol.* **2018**, *56*, 189–198.
- 429 7. Abegunde, A.T.; Muhammad, B.H.; Bhatti, O.; Ali, T. Environmental risk factors for inflammatory bowel
430 diseases: Evidence based literature review. *World J. Gastroenterol.* **2016**, *22*, 6296–6317.
- 431 8. Aleksandrova, K.; Romero-Mosquera, B.; Hernandez, V. Diet, Gut Microbiome and Epigenetics:
432 Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention.
433 *Nutrients* **2017**, *9*.
- 434 9. Ruemmele, F.M. Role of Diet in Inflammatory Bowel Disease. *Ann. Nutr. Metab.* **2016**, *68*, 33–41.
- 435 10. Walton, C.; Montoya, M.P.; Fowler, D.P.; Turner, C.; Jia, W.; Whitehead, R.N.; Griffiths, L.; Waring, R.H.;
436 Ramsden, D.B.; Cole, J.A.; et al. Enteral feeding reduces metabolic activity of the intestinal microbiome
437 in Crohn's disease: an observational study. *Eur. J. Clin. Nutr.* **2016**, *70*, 1052–1056.
- 438 11. Kakodkar, S.; Mutlu, E.A. Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease.
439 *Gastroenterol. Clin. North Am.* **2017**, *46*, 745–767.
- 440 12. Hansen, T.; Duerksen, D.R. Enteral nutrition in the management of pediatric and adult crohn's disease.
441 *Nutrients* **2018**, *10*.
- 442 13. Guagnozzi, D.; González-Castillo, S.; Oliveira, A.; Lucendo, A.J. Nutritional treatment in inflammatory
443 bowel disease. An update. *Rev Esp Enferm Dig* **2012**, *104*, 479–488.
- 444 14. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and
445 meta-analyses: the PRISMA statement. *J. Clin. Epidemiol.* **2009**, *62*, 1006–1012.
- 446 15. Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J.
447 Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control. Clin. Trials*
448 **1996**, *17*, 1–12.
- 449 16. Cascaes da Silva, F.; Valdivia Arancibia, B.A.; da Rosa Iop, R.; Barbosa Gutierrez Filho, P.J.; da Silva, R.
450 Evaluation lists and scales for the quality of scientific studies. *Rev. Cuba. Inf. en Ciencias la Salud* **2013**, *24*,
451 295–312.
- 452 17. Olivo, S.A.; Macedo, L.G.; Gadotti, I.C.; Fuentes, J.; Stanton, T.; Magee, D.J. Scales to Assess the Quality
453 of Randomized Controlled Trials: A Systematic Review. *Phys. Ther.* **2008**, *88*, 156–175.
- 454 18. Nasiri, M.; Gheibi, Z.; Miri, A.; Rahmani, J.; Asadi, M.; Sadeghi, O.; Maleki, V.; Khodadost, M. Effects of
455 consuming date fruits (*Phoenix dactylifera* Linn) on gestation, labor, and delivery: An updated
456 systematic review and meta-analysis of clinical trials. *Complement. Ther. Med.* **2019**, *45*, 71–84.
- 457 19. Baujat, B.; Mahé, C.; Pignon, J.P.; Hill, C. A graphical method for exploring heterogeneity in meta-
458 analyses: Application to a meta-analysis of 65 trials. *Stat. Med.* **2002**, *21*, 2641–2652.
- 459 20. Duval, S.; Tweedie, R. A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in
460 Meta-Analysis. *J. Am. Stat. Assoc.* **2000**, *95*, 89–98.
- 461 21. Copas, J.B.; Shi, J.Q. A sensitivity analysis for publication bias in systematic reviews. *Stat. Methods Med.*
462 *Res.* **2001**, *10*, 251–265.
- 463 22. Schwarzer, G. meta: An R package for meta-analysis. *R News* **2007**, *7*.

- 464 23. Schwarzer, G.; Carpenter, J.R.; Rüker, G. *metasens: Advanced Statistical Methods to Model and Adjust for*
465 *Bias in Meta-Analysis. R package version 0.4-0.*; 2019; ISBN 0000000221.
- 466 24. Sokulmez, P.; Demirbag, A.E.; Arslan, P.; Disibeyaz, S. Effects of enteral nutritional support on
467 malnourished patients with inflammatory bowel disease by subjective global assessment. *Turk. J.*
468 *Gastroenterol.* **2014**, *25*, 493–507.
- 469 25. Hu, D.; Ren, J.; Wang, G.; Li, G.; Liu, S.; Yan, D.; Gu, G.; Zhou, B.; Wu, X.; Chen, J.; et al. Exclusive enteral
470 nutritional therapy can relieve inflammatory bowel stricture in Crohn's disease. *J. Clin. Gastroenterol.*
471 **2014**, *48*, 790–795.
- 472 26. Guo, Z.; Wu, R.; Zhu, W.; Gong, J.; Zhang, W.; Li, Y.; Gu, L.; Li, N.; Li, J. Effect of exclusive enteral
473 nutrition on health-related quality of life for adults with active Crohn's disease. *Nutr. Clin. Pract.* **2014**,
474 *28*, 499–505.
- 475 27. Feng, Y.; Li, Y.; Mei, S.; Zhang, L.; Gong, J.; Gu, L.; Zhang, W.; Zhu, W.; Li, N.; Li, J. Exclusive enteral
476 nutrition ameliorates mesenteric adipose tissue alterations in patients with active Crohn's disease. *Clin.*
477 *Nutr.* **2013**, *October*, 1–9.
- 478 28. Wiese, D.M.; Lashner, B.A.; Lerner, E.; Demichele, S.J.; Seidner, D.L. The effects of an oral supplement
479 enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients. *Nutr.*
480 *Clin. Pract.* **2011**, *26*, 463–473.
- 481 29. Yamamoto, T.; Nakahigashi, M.; Umegae, S.; Matsumoto, K. Prospective clinical trial: enteral nutrition
482 during maintenance infliximab in Crohn's disease. *J. Gastroenterol.* **2010**, *45*, 24–29.
- 483 30. Yamamoto, T.; Nakahigashi, M.; Umegae, S.; Kitagawa, T.; Matsumoto, K. Impact of long-term enteral
484 nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: a prospective, non-
485 randomized, parallel, controlled study. *Aliment. Pharmacol. Ther.* **2007**, *25*, 67–72.
- 486 31. Takagi, S.; Utsunomiya, K.; Kuriyama, S.; Yokoyama, H.; Takahashi, S.; Iwabuchi, M.; Takahashi, H.;
487 Takahashi, S.; Kinouchi, Y.; Hiwatashi, N.; et al. Effectiveness of an "half elemental diet" as maintenance
488 therapy for Crohn's disease: a randomized-controlled trial. *Aliment. Pharmacol. Ther.* **2006**, *24*, 1333–1340.
- 489 32. Bamba, T.; Shimoyama, T.; Sasaki, M.; Tsujikawa, T.; Fukuda, Y.; Koganei, K.; Hibi, T.; Iwao, Y.;
490 Munakata, A.; Fukuda, S.; et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's
491 disease: a randomized, controlled trial. *Eur. J. Gastroenterol. Hepatol.* **2003**, *15*, 151–157.
- 492 33. Gassull, M.A.; Fernández-Bañares, F.; Cabré, E.; Papo, M.; Gíaffer, M.H.; Sánchez-Lombraña, J.L.; Richart,
493 C.; Malchow, H.; González-Huix, F.; Esteve, M. Fat composition may be a clue to explain the primary
494 therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised
495 multicentre European trial. *Gut* **2002**, *51*, 164–168.
- 496 34. Sakurai, T.; Matsui, T.; Yao, T.; Takagi, Y.; Hirai, F.; Aoyagi, K.; Okada, M. Short-term efficacy of enteral
497 nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient
498 formulas. *JPEN. J. Parenter. Enteral Nutr.* **2002**, *26*, 98–103.
- 499 35. Verma, S.; Kirkwood, B.; Brown, S.; Gíaffer, M.H. Oral nutritional supplementation is effective in the
500 maintenance of remission in Crohn's disease. *Dig. liver Dis.* **2000**, *32*, 769–774.
- 501 36. Verma, S.; Brown, S.; Kirkwood, B.; Gíaffer, M.H.H. Polymeric versus elemental diet as primary
502 treatment in active Crohn's disease: a randomized, double-blind trial. *Am. J. Gastroenterol.* **2000**, *95*, 735–
503 739.
- 504 37. Schneeweiss, B.; Lochs, H.; Zauner, C.; Fischer, M.; Wyatt, J.; Maier-Dobersberger, T.; Schneider, B.
505 Energy and substrate metabolism in patients with active Crohn's disease. *J. Nutr.* **1999**, *129*, 844–848.
- 506 38. Royall, D.; Greenberg, G.R.; Allard, J.P.; Baker, J.P.; Jeejeebhoy, K.N. Total enteral nutrition support

- 507 improves body composition of patients with active Crohn's disease. *JPEN. J. Parenter. Enteral Nutr.* **1995**,
508 *19*, 95-99.
- 509 39. Mansfield, J.C.; Giaffer, M.H.; Holdsworth, C.D. Controlled trial of oligopeptide versus amino acid diet
510 in treatment of active Crohn's disease. *Gut* **1995**, *36*, 60-66.
- 511 40. Teahon, K.; Pearson, M.; Smith, T.; Bjarnason, I. Alterations in nutritional status and disease activity
512 during treatment of crohn's disease with elemental diet. *Scand. J. Gastroenterol.* **1995**, *30*, 54-60.
- 513 41. Stolk, M.F.; Van Erpecum, K.J.; Hiemstra, G.; Jansen, J.B.; Van Berge-Henegouwen, G.P. Gallbladder
514 motility and cholecystokinin release during long-term enteral nutrition in patients with Crohn's disease.
515 *Scand. J. Gastroenterol.* **1994**, *29*, 934-939.
- 516 42. Royall, D.; Jeejeebhoy, K.N.; Baker, J.P.; Allard, J.P.; Habal, F.M.; Cunnane, S.C.; Greenberg, G.R.
517 Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional
518 outcome. *Gut* **1994**, *35*, 783-787.
- 519 43. Gonzalez-Huix, F.; de Leon, R.; Fernandez-Banares, F.; Esteve, M.; Cabre, E.; Acero, D.; Abad-Lacruz, A.;
520 Figa, M.; Guilera, M.; Planas, R.; et al. Polymeric enteral diets as primary treatment of active Crohn's
521 disease: a prospective steroid controlled trial. *Gut* **1993**, *34*, 778-782.
- 522 44. Hirakawa, H.; Fukuda, Y.; Tanida, N.; Hosomi, M.; Shimoyama, T. Home elemental enteral
523 hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease.
524 *Gastroenterol. Jpn.* **1993**, *28*, 379-384.
- 525 45. Rigaud, D.; Cosnes, J.; Le Quintrec, Y.; René, E.; Gendre, J.P.; Mignon, M. Controlled trial comparing
526 two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet.
527 *Gut* **1991**, *32*, 1492-1497.
- 528 46. Lochs, H.; Steinhardt, H.J.R.G.; Klaus-wentz, B.; Zeitz, M.; Vogelsang, H.; Sommer, H.; Fleig, W.E.; Bauer,
529 P.; Schirrmester, J.R.G.; Malchow, H. Comparison of Enteral Nutrition and Drug Treatment in Active
530 Crohn ' s Disease Cooperative. *Gastroenterology* **1991**, *101*, 881-888.
- 531 47. Raouf, A.H.; Hildrey, V.; Daniel, J.; Walker, R.J.; Krasner, N.; Elias, E.; Rhodes, J.M. Enteral feeding as
532 sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case
533 study of dietary challenge. *Gut* **1991**, *32*, 702-707.
- 534 48. Wright, R.A.; Adler, E.C. Peripheral parenteral nutrition is no better than enteral nutrition in acute
535 exacerbation of Crohn's disease: a prospective trial. *J. Clin. Gastroenterol.* **1990**, *12*, 396-399.
- 536 49. Giaffer, M.H.; North, G.; Holdsworth, C.D. Controlled trial of polymeric versus elemental diet in
537 treatment of active Crohn's disease. *Lancet (london, england)* **1990**, *335*, 816-819.
- 538 50. Abad-Lacruz, A.; González-Huix, F.; Esteve, M.; Fernández-Bañares, F.; Cabré, E.; Boix, J.; Acero, D.;
539 Humbert, P.; Gassull, M.A. Liver function tests abnormalities in patients with inflammatory bowel
540 disease receiving artificial nutrition: a prospective randomized study of total enteral nutrition vs total
541 parenteral nutrition. *JPEN. J. Parenter. Enteral Nutr.* **1990**, *14*, 618-621.
- 542 51. Greenberg, G.R.; Fleming, C.R.; Jeejeebhoy, K.N.; Rosenberg, I.H.; Sales, D.; Tremaine, W.J. Controlled
543 trial of bowel rest and nutritional support in the management of Crohn's disease. *Gut* **1988**, *29*, 1309-
544 1315.
- 545 52. Harries, A.D.; Jones, L.A.; Danis, V.; Fifield, R.; Heatley, R. V; Newcombe, R.G.; Rhodes, J. Controlled
546 trial of supplemented oral nutrition in Crohn's disease. *Lancet (london, england)* **1983**, *1*, 887-890.
- 547 53. Cuív, P.Ó.; Begun, J.; Keely, S.; Lewindon, P.J.; Morrison, M. Towards an integrated understanding of
548 the therapeutic utility of exclusive enteral nutrition in the treatment of Crohn's disease. *Food Funct.* **2016**,
549 *7*, 1741-51.

- 550 54. Dupont, B.; Dupont, C.; Justum, A.-M.; Piquet, M.-A.; Reimund, J.-M. Enteral nutrition in adult Crohn's
551 disease: Present status and perspectives. *Mol. Nutr. Food Res.* **2008**, *52*, 875–884.
- 552 55. Halmos, E.P.; Gibson, P.R. Dietary management of IBD—insights and advice. *Nat. Rev. Gastroenterol.*
553 *Hepatol.* **2015**, *12*, 133–146.
- 554 56. Ruemmele, F.M.; Pigneur, B.; Garnier-Lengliné, H. Enteral Nutrition as Treatment Option for Crohn's
555 Disease: In Kids Only? In *Nestle Nutrition Institute workshop series*; 2014; Vol. 79, pp. 115–123.
- 556 57. Rubio, A.; Pigneur, B.; Garnier-Lengliné, H.; Talbotec, C.; Schmitz, J.; Canioni, D.; Goulet, O.; Ruemmele,
557 F.M. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated
558 oral vs. continuous enteral feeding. *Aliment. Pharmacol. Ther.* **2011**, *33*, 1332–1339.
- 559 58. Mohri, T.; Matsuda, H.; Kubo, N.; Inadome, N.; Nakamori, Y.; Fujimi, S.; Yoshioka, T. The effect on
560 glycemic control of a low-carbohydrate, high-fat enteral formula in critically ill patients admitted to a
561 trauma and critical care center. *Nihon Kyukyū Igakukai Zasshi* **2011**, *22*, 871–877.
- 562 59. Wewalka, M.; Drolz, A.; Zauner, C. Influence of fat-based versus glucose-based enteral nutrition
563 formulas on glucose homeostasis. *Crit. Care* **2013**, *17*, P250.
- 564 60. Lubbers, T.; Luyer, M.D.P.; de Haan, J.-J.; Hadfoune, M.; Buurman, W.A.; Greve, J.W.M. Lipid-Rich
565 Enteral Nutrition Reduces Postoperative Ileus in Rats via Activation of Cholecystokinin-Receptors. *Ann.*
566 *Surg.* **2009**, *249*, 481–487.
- 567 61. Tan, S.-J.; Yu, C.; Yu, Z.; Lin, Z.-L.; Wu, G.-H.; Yu, W.-K.; Li, J.-S.; Li, N. High-fat enteral nutrition reduces
568 intestinal mucosal barrier damage after peritoneal air exposure. *J. Surg. Res.* **2016**, *202*, 77–86.
- 569 62. Xie, C.; Lin, J.; Su, J.; Ren, J. Synergistic effect of enteral nutrition on remission induction in a patient with
570 penetrating Crohn disease. *Medicine (Baltimore)*. **2019**, *98*, e16750.
- 571 63. Lochs, H.; Steinhardt, H.J.; Klaus-Wentz, B.; Zeitz, M.; Vogelsang, H.; Sommer, H.; Fleig, W.E.; Bauer, P.;
572 Schirrmester, J.; Malchow, H. Comparison of enteral nutrition and drug treatment in active Crohn's
573 disease. Results of the European Cooperative Crohn's Disease Study. IV. *Gastroenterology* **1991**, *101*, 881-
574 888.
- 575 64. Papi, C.; Fasci-Spurio, F.; Rogai, F.; Settesoldi, A.; Margagnoni, G.; Annese, V. Mucosal healing in
576 inflammatory bowel disease: Treatment efficacy and predictive factors. *Dig. Liver Dis.* **2013**, *45*, 978–985.
- 577 65. Armuzzi, A.; Van Assche, G.; Reinisch, W.; de Chambrun, G.P.; Griffiths, A.; Sladek, M.; Preiss, J.C.;
578 Lukas, M.; D'Haens, G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies
579 to enhance intestinal healing in inflammatory bowel disease. *J. Crohn's Colitis* **2012**, *6*, 492–502.
- 580 66. Nahidi, L.; Day, A.S.; Lemberg, D.A.; Leach, S.T. Differential effects of nutritional and non-nutritional
581 therapies on intestinal barrier function in an in vitro model. *J. Gastroenterol.* **2012**, *47*, 107–117.
- 582 67. Teahon, K.; Smethurst, P.; Pearson, M.; Levi, A.J.; Bjarnason, I. The effect of elemental diet on intestinal
583 permeability and inflammation in Crohn's disease. *Gastroenterology* **1991**, *101*, 84–89.
- 584 68. Ahmad, S.J.; Khan, A.; Madhotra, R.; K Exadaktylos, A.; Milioto, M.E.; Macfaul, G.; Rostami, K. Semi-
585 elemental diet is effective in managing high output ileostomy; a case report. *Gastroenterol. Hepatol. from*
586 *bed to bench* **2019**, *12*, 169–173.
- 587 69. Rostami, K.; Al Dulaimi, D. Elemental diets role in treatment of high ileostomy output and other
588 gastrointestinal disorders. *Gastroenterol. Hepatol. from bed to bench* **2015**, *8*, 71–6.
- 589 70. Sokulmez, P.; Demirbag, A.E.; Arslan, P.; Disibeyaz, S.; Sökülmez, P.; Demirbağ, A.E.; Arslan, P.;
590 Dişibeyaz, S. Effects of enteral nutritional support on malnourished patients with inflammatory bowel
591 disease by subjective global assessment. *Turkish J. Gastroenterol.* **2014**, *25*, 493–507.
- 592 71. Damas, O.M.; Garces, L.; Abreu, M.T. Diet as Adjunctive Treatment for Inflammatory Bowel Disease:

- 593 Review and Update of the Latest Literature. *Curr. Treat. Options Gastroenterol.* **2019**, *17*, 313–325.
- 594 72. Voitk, A.J.; Echave, V.; Feller, J.H.; Brown, R.A.; Gurd, F.N. Experience with elemental diet in the
595 treatment of inflammatory bowel disease. Is this primary therapy? *Arch. Surg.* **1973**, *107*, 329.
- 596 73. Ruemmele, F.M.; Roy, C.C.; Levy, E.; Seidman, E.G. Nutrition as primary therapy in pediatric Crohn's
597 disease: Fact or fantasy? *J. Pediatr.* **2000**, *136*, 285–291.
- 598 74. Johnson, T.; Macdonald, S.; Hill, S.M.; Thomas, A.; Murphy, M.S. Treatment of active Crohn's disease in
599 children using partial enteral nutrition with liquid formula: a randomised controlled trial. *Gut* **2006**, *55*,
600 356-361.
- 601 75. Fell, J.M.; Paintin, M.; Arnaud-Battandier, F.; Beattie, R.M.; Hollis, A.; Kitching, P.; Donnet-Hughes, A.;
602 MacDonald, T.T.; Walker-Smith, J.A. Mucosal healing and a fall in mucosal pro-inflammatory cytokine
603 mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. *Aliment. Pharmacol. Ther.*
604 **2000**, *14*, 281–9.
- 605 76. Wedlake, L.; Slack, N.; Andreyev, H.J.N.; Whelan, K. Fiber in the treatment and maintenance of
606 inflammatory bowel disease: a systematic review of randomized controlled trials. *Inflamm. Bowel Dis.*
607 **2014**, *20*, 576–586.
- 608 77. Scolapio, J.S. The Role of Total Parenteral Nutrition in the Management of Patients With Acute Attacks
609 of Inflammatory Bowel Disease. *J. Clin. Gastroenterol.* **1999**, *29*, 223–224.
- 610 78. Storck, L.J.; Imoberdorf, R.; Ballmer, P.E. Nutrition in Gastrointestinal Disease: Liver, Pancreatic, and
611 Inflammatory Bowel Disease. *J. Clin. Med.* **2019**, *8*, 1098.
- 612 79. Griffiths, A.M. Enteral Nutrition in the Management of Crohn's Disease. *J. Parenter. Enter. Nutr.* **2005**, *29*,
613 S108–S117.
- 614